Real Psychiatry: A Live Virtual Educational Experience Designed for and by Advanced Practice Professionals on the Frontlines of Modern Practice

January 13, 2024

Program Description

Mental health disorders have long been a leading contributor to global disease burden, but several years marked by pandemic have led to a spike in prevalence, the effects of which may be palpable well into the future. In this milieu, of and demand for advanced practice professionals (APPs) in this space has risen exponentially. In particular, nurse practitioners (NPs) from all levels of experience are rising to meet this need. But despite organizations’ increasing efforts to create continuing education for APPs, a recent EfficientCME survey of NPs reveals that their needs and preferences are still not being sufficiently met across most domains including instructional design (e.g., lecture vs case-based) and featured speakers (e.g., physician vs NP). Correspondingly, many NPs feel insufficiently prepared to manage multiple aspects of real psychiatric care.

To help improve the translation from education to practice, EfficientCME and Partners for Advancing Clinical Education (PACE) have created an experience tailored to meet the needs of this group from trainee all the way through early-career and established APPs so that they can better navigate the ever-evolving foundational and practical hurdles of pervasive mental health needs. The full day, virtual psychiatry immersion conference is designed for and by advanced practitioners with an emphasis on hands-on learning and evidence-based clinical implementation.

Target Audience

This activity is intended for advanced practice professionals caring for patients with common psychiatric disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
  • Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
  • Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Course summary
Course opens: 
11/07/2023
Course expires: 
01/13/2024
Event starts: 
01/13/2024 - 8:00am EST
Event ends: 
01/13/2024 - 4:30pm EST
Cost:
$0.00
Rating: 
5

Slide Decks

Welcome Address
PDF iconWelcome Address_.pdf
Intersecting Indications: The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management
PDF iconIntersecting_.pdf
Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics
PDF iconAntipsychotics.pdf
Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs
PDF iconRoad Map.pdf
The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience
PDF iconThe Real Schizophrenia.pdf
Turning the Tide in Bipolar Depression
PDF iconTurning the Tide in Bipolar Depression.pdf
Extrapyramidal Symptoms: When are They Tardive Dyskinesia?
PDF iconExtrapyramidal Symptoms.pdf
The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies
PDF iconThe Changing Face of MDD.pdf
Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan
PDF iconADHD.pdf
Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment
PDF iconSUD.pdf
Closing Remarks
PDF iconClosing Remarks_.pdf
Glossary
PDF iconBrand Names.pdf

Welcome Address 8:00 am - 8:10 am (10 min)

Intersecting Indications: The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management 8:10 am - 8:55 am (45 min)

Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics 8:55 am - 9:55 am (60 min)

Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs 10:10 am - 10:35 am (25 min)

The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience 10:35 am - 11:25 am (50 min)

Turning the Tide in Bipolar Depression 11:25 am - 12:10 pm (45 min)

Extrapyramidal Symptoms: When are They Tardive Dyskinesia? 1:10 pm - 1:55 pm (45 min)

The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies 1:55 pm - 2:40 pm (45 min)

Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan 2:50 pm - 3:35 pm (45 min)

Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment 3:35 pm - 4:05 pm (30 min)

Closing Remarks 4:05 pm - 4:15 pm (10 min)

   Carmen Kosicek, MSN, APNP, PMHNP-BC (Chair)
   CEO, Founder, Provider
   Alay Health Team
   
 
 
 
 
 
   Ann Barbaro, MSN, APRN, PMHNP-BC
   Psychiatric-Mental Health Nurse Practitioner
   Alay Health Team
   
 
 
 
 
 
   Leslie Citrome, MD, MPH
   Clinical Professor, Psychiatry and Behavioral Sciences
   New York Medical College
   
 
 
 
 
 
   Bobbi Jo Durst, MSN, APNP, PMHNP- BC
   Psychiatric Mental Health Nurse Practitioner
   Alay Health Team / Delke & Dursahl LLC
 
 
 
 
 
 
 
   Shannon Eaton, MSN, APN, PMHNP-BC
   Psychiatric Nurse Practitioner
   Mindful Therapy Group
 
 
 
 
 
 
   Christina Fuchs, DNP, PMHNP- BC
   Psychiatric Mental Health Nurse Practitioner
   Wisconsin Correctional Prisons
   
 
 
 
 
 
   Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC
   Psychiatric-Mental Health Nurse Practitioner
   SPGPM2 Services, LLC
 
 
 
 
 
 
   Karen J Greene MSN, Ed, APRN, FNP-C, PMHNP-BC
   Owner
   Mountainside Healthcare LLC
 
 
 
 
 
 
   Amber Hoberg, MSN, APRN, PMHNP-BC
   Psychiatric Mental Health Nurse Practitioner
   Morningstar Family Medicine / Baptist Health System
 
 
 
 
 
 
 
 
 
   Mark Jankelow MSN, BA, PMHNP-BC
   Psychiatric Mental Health Nurse Practitioner; CEO/Owner
   Springbok Health, Inc
 
 
 
 
 
   Mia W. Jones, MSN, APRN, PMHNP-BC
   Psychiatric Mental Health Nurse Practitioner  
   Gupta Psychiatry
 
 
 
 
   Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B
   Nurse Practitioner
   Seaside Behavioral Health
 
 
 
 
 
 
 
   Chelsea Schwartz, MSN, APRN, PMHNP-BC
   Psychiatric Mental Health Nurse Practitioner
   Alay Health Team
 
 
 
 
 

 

“Phone a Pharmacist” Faculty

Jasper Cayanga, RPh
Amy De Guzman, RPh
Era Cassandra I. Lopez, RPh

To receive CE credit, please follow these steps:

For Physicians, Nurses, and Others (excluding Psychologists):

  1. Visit: https://paceducation.com/RealPsychiatry
  2. Complete the activity evaluation
  3. Upon completion of all evaluation questions your credit will be made available for download immediately.

For Psychologists:

  1. Visit: https://paceducation.com/RealPsychiatryAPA
  2. Select a session attended and complete the activity evaluation
  3. Upon completion of all evaluation questions your credit will be made available for download immediately.
  4. To return to the session listing and claim additional credits, click on the above link to return to the homepage. 

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.

 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Physician Continuing Education
PACE designates this live activity for a maximum of  7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 7.0 contact hours.
 
PA Continuing Medical Education
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for  7.0  AAPA Category 1 CME  credits. PAs should only claim credit commensurate with the extent of their participation.
 
Psychologist Continuing Education
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
 
Credit Designation
This program offers 7.0 continuing education credits for psychologists.
 

Upon completion of these sessions, psychologist participants should be able to:

Intersecting Indications The Challenges and Opportunities of Clinical Overlap in Upgrading Patient Management (0.75 credit)
  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
  • Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
  • Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics (1.0 credit)
  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs (0.5 credit)
  • Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience (0.75 credit)
  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
  • Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Turning the Tide in Bipolar Depression (0.75 credit)
  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Extrapyramidal Symptoms: When are They Tardive Dyskinesia? (0.75 credit)
  • Recognize overlapping symptomology of psychiatric conditions and the transdiagnostic roles of psychotropic medications to more effectively identify complicated individual presentations and simplify treatment plans
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Develop evidence-based approaches to medication changes (e.g., dose adjustment, cross-tapering, stopping) to reduce polypharmacy, improve adherence, and minimize adverse effects
  • Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
  • Identify updated strategies for prioritizing considerations for complex case management (e.g., psychiatric/medical comorbidity, iatrogenic movement disorder) to maximize symptom reduction and minimize safety risks
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies (0.75 credit)
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Formulate critical documentation and reimbursement strategies across psychiatric conditions to expand fiscal obtainability of modern evidence-based treatments for patients
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan (0.75 credit)
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment (0.5 credit)
  • Differentiate the pharmacokinetic and pharmacodynamic profiles between individual agents of major psychotropic medication classes to develop evidence-based, customized treatment plans that optimize individual patient response
  • Recognize new developments (e.g., extended-release technology, formulations) that may enhance the delivery of and patient comfort with pharmacotherapeutics to customize treatment options to individual patients
  • Evaluate novel targets and mechanisms of action of recently approved and investigational pharmacotherapeutics to determine their current or future roles in improving patient outcomes
  • Assess practical considerations (e.g., support systems) for effective patient-centered communication to establish trust and facilitate commitment to care
Certificate of Participation for Other Healthcare Professionals
A Certificate of Participation will be given upon completion of the activity enabling participants to register their credit with the appropriate licensing boards or associations.

Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Carmen Kosicek, MSN, APNP, PMHNP-BC reported the following relationships:
  • Consulting Fees: AbbVie, Boehringer Ingelheim, Corium, Eisai, Intra-Cellular, Teva
  • Speakers Bureau: AbbVie/Allergan, Alkermes, Intra-Cellular, Teva, US World Meds

Ann Barbaro, MSN, APRN, PMHNP-BC has no financial relationships to disclose.

Leslie Citrome, MD, MPH  reported the following relationships:

  • Contracted Research: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona
  • Consulting Fees: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, and Teva

Bobbi Jo Durst, MSN, APNP, PMHNP- BC has no financial relationships to disclose.

Shannon Eaton, MSN, APN, PMHNP-BC has no financial relationships to disclose.

Christina Fuchs, DNP, PMHNP-BC has no financial relationships to disclose.

Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC has no financial relationships to disclose.

Karen J Greene MSN, Ed, APRN, FNP-C, PMHNP-BC has no financial relationships to disclose.

Amber Hoberg, MSN, APRN, PMHNP-BC reported the following relationships:

  • Consulting Fees: Alkermes, Intra-Cellular, Karuna, Neurocrine, Teva
  • Spealers Bureau: Acadia, BioXcel, Intra-Cellular, Neurocrine, Otsuka, Teva

Mark Jankelow MSN, BA, PMHNP-BC reported the following relationships:

  • Consulting Fees: AbbVie, Alkermes, and Teva
  • Speakers Bureau: AbbVie, Alkermes, and Teva

Mia W. Jones, MSN, APRN, PMHNP-BC has no financial relationships to disclose.

Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B reported the following relationships:

  • Consulting Fees: AbbVie, Johnson & Johnson, and Teva
  • Speakers Bureau: AbbVie, Biogen/Sage, Johnson & Johnson, Neurocrine, and Teva

Chelsea Schwartz, MSN, APRN, PMHNP-BC has no financial relationships to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Efficient LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by independent educational grants from Indivior Inc., Intra-Cellular Therapies, Inc., Teva Pharmaceuticals, and Tris Pharma, Inc.

Price

Cost:
$0.00
Please login or register to take this course.

Please click "Take course" to register for the Real Psychiatry Conference.